News Release

12.21, 2011

Favorable Immunogenicity and Tolerability Observed in Phase I/II Clinical Trial for Seasonal Flu Vaccine UMN-0502 (ASP7374)

11.11, 2011

Administration of H5N1 Influenza Vaccine UMN-0501 (ASP7373) Completed in Phase II Clinical Trial

9.15, 2011

Administration of Seasonal Flu Vaccine UMN-0502 (ASP7374) Completed in Phase I/II Clinical Trial

7.1, 2011

UMN Pharma CEO, Shu-ichi Kanazashi, Makes Special-Session Presentation at 10th Int'l Bio Expo Japan, 2011

4.1, 2011

Akita Plant Commenced Operations: A new manufacturing technology development center

All News Release